{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:48:43Z","timestamp":1780418923770,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jpba.2022.115214","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T11:33:23Z","timestamp":1672313603000},"page":"115214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Isolation and characterization of pseudo degradation products of acalabrutinib using ESI-HRMS\/MS and NMR: Formation of possible geometrical isomers"],"prefix":"10.1016","volume":"225","author":[{"given":"Samikshya","family":"Panda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitalee","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravikanth Reddy","family":"Kandula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Gajjela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Durga Harish","family":"Ravuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemantha","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Kalamse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhararao","family":"Bagadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2022.115214_bib1","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1158\/1538-7445.AM2015-2596","article-title":"Abstract 2596: ACP-196: a novel covalent Bruton\u2019s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients","volume":"75","author":"Covey","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2022.115214_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2022.115214_bib3","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V126.23.2908.2908","article-title":"ACP-196 is a second-generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity","volume":"126","author":"Harrington","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2022.115214_bib4","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1538-7445.AM2014-1744","article-title":"Abstract 1744: ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma","volume":"74","author":"Gardner","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2022.115214_bib5","doi-asserted-by":"crossref","first-page":"eabd0110","DOI":"10.1126\/sciimmunol.abd0110","article-title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19","volume":"5","author":"Roschewski","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jpba.2022.115214_bib6","unstructured":"ICH Q1A(R2) guidelines, stability testing of new drug substances and products, 4 version, dated 6 February 2003."},{"key":"10.1016\/j.jpba.2022.115214_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.trac.2013.05.006","article-title":"Forced degradation studies to assess the stability of drugs and products","volume":"49","author":"Singh","year":"2013","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2022.115214_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1208\/s12249-013-0047-x","article-title":"Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: predicting degradation related impurities and impurity considerations for pharmaceutical dosage forms","author":"Alsante","year":"2014","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.jpba.2022.115214_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.22270\/jddt.v10i2-s.4040","article-title":"Current trend in performance of forced degradation studies for drug substance and drug product\u2019s","volume":"10","author":"Rajveer","year":"2020","journal-title":"J. Drug Deliv. Ther."},{"key":"10.1016\/j.jpba.2022.115214_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs-a review","volume":"4","author":"Blessy","year":"2014","journal-title":"J. Pharm. Ana"},{"key":"10.1016\/j.jpba.2022.115214_bib11","first-page":"165","article-title":"A review article on development of forced degradation and stability indicating studies for drug substance and drug product","volume":"9","author":"Patel","year":"2019","journal-title":"J. Pharm. Sci. Biosci. Res."},{"key":"10.1016\/j.jpba.2022.115214_bib12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.5958\/0974-360X.2019.00152.5","article-title":"A review: stability indicating forced degradation studies","volume":"12","author":"Sutar","year":"2019","journal-title":"Res. J. Pharma Tech."},{"key":"10.1016\/j.jpba.2022.115214_bib13","first-page":"465","article-title":"Development and validation of RP-HPLC method for determination of new anticancer agent Acalabrutinib in bulk and its pharmaceutical formulation","volume":"6","author":"Priyanka","year":"2019","journal-title":"Eur. J. Biomed. Pharma. Sci."},{"key":"10.1016\/j.jpba.2022.115214_bib14","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.14233\/ajchem.2020.22844","article-title":"Development and validation of novel HPLC bioanalytical analysis method for acalabrutinib: an anticancer drug in human plasma","volume":"32","author":"Krishna","year":"2020","journal-title":"Asian J. Chem."},{"key":"10.1016\/j.jpba.2022.115214_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113613","article-title":"Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS\/MS and its application to a pharmacokinetic study","volume":"191","author":"Jiang","year":"2020","journal-title":"J. Pharma. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115214_bib16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jpba.2018.11.012","article-title":"Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS\/MS method: an application to pharmacokinetic study in Sprague Dawley rats","volume":"164","author":"Surendran","year":"2019","journal-title":"J. Pharma. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115214_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109559","article-title":"Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro","volume":"345","author":"Han","year":"2021","journal-title":"Chem. -Biol. Interact."},{"key":"10.1016\/j.jpba.2022.115214_bib18","first-page":"2758","article-title":"Stability indicating RP-HPLC method development and validation for the determination of Acalabrutinib in bulk drug and capsule dosage form","volume":"8","author":"Anusha","year":"2019","journal-title":"Intern. J. Bio-Pharma. Res."},{"key":"10.1016\/j.jpba.2022.115214_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115077","article-title":"Structural characterization of novel hydrolytic and oxidative degradation products of acalabrutinib by LC-Q-TOF-MS, H\/D exchange and NMR","volume":"221","author":"Kushwah","year":"2022","journal-title":"J. Pharma. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115214_bib20","series-title":"Introduction to Modern Liquid Chromatography","first-page":"403","article-title":"Gradient elution","author":"Snyder","year":"2009"},{"key":"10.1016\/j.jpba.2022.115214_bib21","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1039\/c3gc41260a","article-title":"H2O2-mediated oxidative formation of amides from aromatic amines and 1,3-diketones as acylation agents via C\u2013C bond cleavage at room temperature in water under metal-free conditions","volume":"12","author":"Sun","year":"2013","journal-title":"Green. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522006355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522006355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:25:43Z","timestamp":1760001943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522006355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":21,"alternative-id":["S0731708522006355"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115214","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolation and characterization of pseudo degradation products of acalabrutinib using ESI-HRMS\/MS and NMR: Formation of possible geometrical isomers","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115214"}}